Kamal Shemisa, MD
Cardiovascular Disease · Cincinnati, OHNPI 1326281007
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $262,786 of the $313,897 with a category attached, or 83.7%. It is spread thinly across 42 manufacturers, the largest accounting for just 19.2%. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 960 payments — averaging $326.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$60K
- Bayer$48K
- Pfizer$36K
- Lilly USA, LLC$32K
- Lexicon Pharmaceuticals, Inc.$32K
- Merck$28K
- plus $78K from 36 others
Across 20 payments — averaging $5227.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$45K
- Amgen$43K
- AstraZeneca$16K
What the payments were for
- Consulting fees$20,5987%
- Speaking & faculty fees$262,78684%
- Travel & lodging$7,1462%
- Food & beverage$23,0177%
- Education$3510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$313,897 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 91 | $2,692,424 |
| OzempicSemaglutide | 350 | $365,280 |
| JardianceEmpagliflozin | 252 | $217,951 |
| WegovySemaglutide | 136 | $188,280 |
| EliquisApixaban | 149 | $166,395 |
| XareltoRivaroxaban | 113 | $120,968 |
| CamzyosMavacamten | 13 | $102,810 |
| EntrestoSacubitril/Valsartan | 99 | $98,569 |
| FarxigaDapagliflozin Propanediol | 119 | $92,348 |
| Repatha SureclickEvolocumab | 74 | $53,375 |
| VerquvoVericiguat | 51 | $44,092 |
| RybelsusSemaglutide | 30 | $30,178 |
| TrulicityDulaglutide | 27 | $27,771 |
| KerendiaFinerenone | 28 | $26,857 |
| MounjaroTirzepatide | 19 | $24,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $35,702 | $2,858,818240 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $1,421 | $583,739516 claims |
| Boehringer IngelheimJardiance | $60,272 | $217,951252 claims |
| Johnson & JohnsonXarelto | $24,314 | $120,968113 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $262 | $102,81013 claims |
| NovartisEntresto | $7,457 | $98,56999 claims |
| AstraZenecaFarxiga | $7,974 | $92,348119 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $32,173 | $52,18546 claims |
| MerckVerquvo | $28,267 | $44,09251 claims |
| BayerKerendia | $47,998 | $26,85728 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $31,983 | $11,93413 claims |
| AmgenCorlanor | $844 | $10,97113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Cincinnati
- Richard BaeCincinnati$136K
- Dylan SteenCincinnati$91K
- Joel FormanCincinnati$64K
- Freidoon GhaziCincinnati$56K
- Wojciech MazurCincinnati$44K
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.